BERLIN, Aug 5 (Reuters) - Merck KGaA raised its outlook after posting forecast-beating second quarter profits on Thursday, boosted by demand for its lab gear and supplies from pharma companies making treatments and vaccines against the coronavirus.

Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 46.7% to 1.6 billion euros ($1.89 billion), above the consensus estimate of 1.46 billion euros in a poll of analysts shared by the company. ($1 = 0.8448 euros) (Reporting by Douglas Busvine Editing by Tomasz Janowski)